The week in pharma: action, reaction and insight - week to November 12, 2021

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell

Significant news last week including UK Pharma major GlaxoSmithKline releasing positive new data on its daprodustat as a new option for anemia in kidney disease. Deal-making developments featured Pfizer entering an agreement that could cost it up to $1.2 billion to gain certain rights to Biohaven Pharma’s migraine drug Nurtec. Also, Roche subsidiary Genentech inked a license and research collaboration with US start-up Novome Biotechnologies on inflammatory bowel disease (IBD). Meantime, Japan’s Kyowa Kirin gained a positive recommendation for its rare blood cancer drug Poteligeo from the UK’ health technology assessor the NICE. Additionally, health care giant Johnson & Johnson surprised markets, with the announcement that it is splitting out its Consumer Health business into a separate publicly-traded company.

GlaxoSmithKline’s daprodustat delivers

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical